Author
Listed:
- Satoshi Inoue
(The University of Tokyo
National Cancer Center Research Institute)
- Yasushi Hirota
(The University of Tokyo)
- Toshihide Ueno
(National Cancer Center Research Institute)
- Yamato Fukui
(The University of Tokyo)
- Emiko Yoshida
(Juntendo University Faculty of Medicine)
- Takuo Hayashi
(Juntendo University Faculty of Medicine)
- Shinya Kojima
(National Cancer Center Research Institute)
- Reina Takeyama
(National Cancer Center Research Institute)
- Taiki Hashimoto
(National Cancer Center Hospital)
- Tohru Kiyono
(National Cancer Center Research Institute)
- Masako Ikemura
(The University of Tokyo)
- Ayumi Taguchi
(The University of Tokyo)
- Tomoki Tanaka
(The University of Tokyo)
- Yosuke Tanaka
(National Cancer Center Research Institute)
- Seiji Sakata
(The Cancer Institute, Japanese Foundation for Cancer Research)
- Kengo Takeuchi
(The Cancer Institute, Japanese Foundation for Cancer Research
The Cancer Institute, Japanese Foundation for Cancer Research
The Cancer Institute, Japanese Foundation for Cancer Research)
- Ayako Muraoka
(Nagoya University Graduate School of Medicine)
- Satoko Osuka
(Nagoya University Graduate School of Medicine)
- Tsuyoshi Saito
(Juntendo University Faculty of Medicine)
- Katsutoshi Oda
(The University of Tokyo)
- Yutaka Osuga
(The University of Tokyo)
- Yasuhisa Terao
(Juntendo University Faculty of Medicine)
- Masahito Kawazu
(The University of Tokyo
National Cancer Center Research Institute)
- Hiroyuki Mano
(National Cancer Center Research Institute)
Abstract
Uterine adenomyosis is a benign disorder that often co-occurs with endometriosis and/or leiomyoma, and impairs quality of life. The genomic features of adenomyosis are unknown. Here we apply next-generation sequencing to adenomyosis (70 individuals and 192 multi-regional samples), as well as co-occurring leiomyoma and endometriosis, and find recurring KRAS mutations in 26/70 (37.1%) of adenomyosis cases. Multi-regional sequencing reveals oligoclonality in adenomyosis, with some mutations also detected in normal endometrium and/or co-occurring endometriosis. KRAS mutations are more frequent in cases of adenomyosis with co-occurring endometriosis, low progesterone receptor (PR) expression, or progestin (dienogest; DNG) pretreatment. DNG’s anti-proliferative effect is diminished via epigenetic silencing of PR in immortalized cells with mutant KRAS. Our genomic analyses suggest that adenomyotic lesions frequently contain KRAS mutations that may reduce DNG efficacy, and that adenomyosis and endometriosis may share molecular etiology, explaining their co-occurrence. These findings could lead to genetically guided therapy and/or relapse risk assessment after uterine-sparing surgery.
Suggested Citation
Satoshi Inoue & Yasushi Hirota & Toshihide Ueno & Yamato Fukui & Emiko Yoshida & Takuo Hayashi & Shinya Kojima & Reina Takeyama & Taiki Hashimoto & Tohru Kiyono & Masako Ikemura & Ayumi Taguchi & Tomo, 2019.
"Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations,"
Nature Communications, Nature, vol. 10(1), pages 1-13, December.
Handle:
RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-13708-y
DOI: 10.1038/s41467-019-13708-y
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-13708-y. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.